Combination therapy of intravitreal triamcinolone and photodynamic therapy with verteporfin for subfoveal choroidal neovascularization

Indian Journal of Ophthalmology

Volumn 54, Issue 4, 2006, Pages 247-250

  Hussain, Nazimul ^a,b   Das, Taraprasad ^a   Rawal, Hema ^a   Kallukuri, Sumasri B ^a   Ram, L S Mohan ^a   Khanna, Rohit ^b  

^a Smt Kanuri Santhamma Retina Vitreous Center   (India)

^b L V PRASAD EYE INSTITUTE   (India)

Author keywords

Intravitreal triamcinolone; photodynamic therapy; subfoveal choroidal neovascularization

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EYE; FEMALE; FOLLOW UP; HUMAN; INTERVENTION STUDY; INTRAOCULAR PRESSURE; MALE; MONOTHERAPY; PHOTODYNAMIC THERAPY; PROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; TREATMENT OUTCOME; VISION TEST;

EID: 33750989629     PISSN: 03014738     EISSN: 03014738     Source Type: Journal    
DOI: 10.4103/0301-4738.27949     Document Type: Article

References (11)

1. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch ophthalmol 1999;117:1329-45.
2. Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001;119:198-207.
3. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularisation in age related macular degeneration: Two-year results of a randomized clinical trial with occult no classic choroidal neovascularistion - verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001;131:541-60.
4. Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE, Gragoudas ES, et al. Verteporfin therapy of subfoveal choroidal neovascularisation in patients with age related macular degeneration. Additional information regarding baseline lesion compositions impact on visual outcome. TAP Report No. 3. Arch Ophthalmol 2002;120:1443-54.
5. Azab M, Boyer DS, Bressler NM, Bressler SB, Cihelkova I, Hao Y, et al. Verteporfin therapy of subfoveally minimally classic choroidal neovascularisation in age related macular degeneration. 2 - year results of a randomized clinical trial. Arch Ophthalmol 2005;123:448-57.
6. Schmidt - Erfurth U, Michels S, Barbazetto I, Laqua H. Photodynamic effects on choroidal neovascularisation and physiological choroids. Invest Ophthalmol Vis Sci 2002;43:830-41.
7. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003;110:1517-25.
8. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005;112:301-4.
9. Schmidt-Erfurth U, Schlotzer-schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3 and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003;44:4473-80.
10. Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust NZ J Ophthalmol 1998;26:277-81.
11. Rechtman E, Danis RP, Pratt LM, Harris A. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 2004;88:344-7.